¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹À¯¹æ¾ÏÇÐȸ (¿Â¶óÀÎ) 2021 School of Breast Disease : 2021-08-21

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Çѱ¹À¯¹æ¾ÏÇÐȸ (¿Â¶óÀÎ) 2021 School of Breast Disease : 2021-08-21
±³À°ÀÏÀÚ : 2021-08-21
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 School of Breast Disease
ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060  
À̸ÞÀÏ : kbcs@kbcs.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ08:30~08:55 Breast imaging: MMG Tomo US  ½ÅÈñÁ¤(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ08:55~09:20 Breast imaging: MRI and Other Breast Imaging Tool  ¼Û¼ºÀº(°í´ë¾È¾Ïº´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ09:20~09:45 Breast pathology: surgical pathology issues of practical importance  À¯ÇѼ®(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ09:45~10:10 Breast cancer staging & biomarker  ÀÌÀº½Å(°í´ë¾È¾Ïº´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ10:10~10:35 Management of benign breast disease  È«¼öÁ¤(¾Æ»êÀ¯¿Ü°ú) 
È޽Ġ08-21 ¿Â¶óÀΠ10:35~10:55 È޽Ġ () 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ10:55~11:20 Surgical Consideration for the primary tumor: mastectomy & BCS, oncoplastic procedure  ¹Ú¼º¹Î(ÃæºÏ´ëÇб³º´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ11:20~11:45 Surgical Consideration for the axilla: SLNBx & ALND  ÀÌÇѺ°(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ11:45~12:10 Introduction of endoscopic & robotic breast surgery  ±èÁö¿¹(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ12:10~12:35 Adjuvant radiation therapy after breast conserving therapy  ±è³ª¸®(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ12:35~13:00 Postmastectomy radiation and RT in metastatic breast cancer  ±è±Ôº¸(ÀÌ´ë¸ñµ¿º´¿ø) 
½Ä»ç 08-21 ¿Â¶óÀΠ13:00~14:00 ½Ä»ç  () 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ14:00~14:30 Adjuvant/neoadjuvant chemotherapy  ÀÌ´ë¿ø(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ14:30~15:00 Adjuvant/neoadjuvant endocrine therapy  Á¤ÀçÇÐ(À»Áö´ëÇб³º´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ15:00~15:30 Adjuvant/neoadjuvant targeted therapy  ±è¹Îȯ(¼¼ºê¶õ½ºº´¿ø) 
È޽Ġ08-21 ¿Â¶óÀΠ15:30~15:50 È޽Ġ () 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ15:50~16:20 Emerging therapy for TN breast cancer  ÀÓ½ÂÅÃ(¿øÁÖ¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ16:20~16:50 Metastatic HER2 positive breast cancer  ¼­°æÁø(ºÐ´ç¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 08-21 ¿Â¶óÀΠ16:50~17:20 Hormone dependent metastatic breast cancer  À̼öÀÌ(µ¿¾Æ´ëÇб³º´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹À¯¹æ¾ÏÇÐȸ (¿Â¶óÀÎ) 2021 School of Breast Disease : 2021-08-21""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ºÎ»ê¼Ò¾Æû¼Ò³â°ú Áöȸ ½ÉÆ÷Áö¾ö : 2021-08-21
´ÙÀ½±Û ´ëÇÑ´ç´¢º´ÇÐȸ (¿Â¶óÀÎ) 8¿ù EGDM (Essential Guideline to Diabetes Management) : 2021-08-21
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
333 ¼­¿ï 2018³â ´ëÇÑ¿Ü°úÀÇ»çȸ Ã߰迬¼ö°­Á : 2018-09-02 1 3,027 2018-08-08
332 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part4,1ÀÏÂ÷) : 2018-09-01 0 435 2018-08-08
331 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part4,1ÀÏÂ÷) : 2018-09-01 0 1,007 2018-08-08
330 ÃæºÏ ´ëÇѼҾưúÇÐȸ ÃæºÏ ¼Ò¾Æû¼Ò³â°ú ¿¬¼ö°­Á : 2018-09-01 0 600 2018-08-08
329 ÀüºÏ Á¦20ȸ ¿µÈ£³²³»ºÐºñ´ë»çÇÐȸ Çмú´ëȸ : 2018-09-01 0 654 2018-08-08
328 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¿¬¼¼º´¸® ½ÉÆ÷Áö¿ò : 2018-09-01 0 642 2018-08-08
327 ¼­¿ï ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø ½Å°æ¿Ü°ú ½ÉÆ÷Áö¾ö : 2018-08-31 0 894 2018-08-08
326 ¼­¿ï Á¦ 4ȸ ´ëÇÑÇǺÎÁø±ÕÇÐȸ ¿¬¼ö±³À° : 2018-08-31 0 514 2018-08-08
325 ÀüºÏ Á¦20ȸ ¿µÈ£³²³»ºÐºñ´ë»çÇÐȸ Çмú´ëȸ : 2018-08-31 0 1,189 2018-08-08
324 ´ë±¸ ´ë±¸°æºÏ°³¿ø³»°úÀÇ»çȸ ¿¬¼ö°­Á : 2018-08-28 0 1,017 2018-08-08
323 ¼­¿ï ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ºÒ¸éÁõ ÀÎÁöÇൿġ·á : 2018-08-26 0 1,646 2018-08-08
322 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø Á¦ 23ȸ °¡Å縯 ¾È°ú Çмú ½ÉÆ÷Áö¾ö : 2018-08-26 0 1,625 2018-08-08
321 ¼­¿ï ´ëÇÑ°³¿øÀÇÇùÀÇȸ 2018³âµµ Á¦2Â÷ ȸ¿ø¿¬¼ö±³À° : 2018-08-26 0 4,052 2018-08-08
320 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part3, 2ÀÏÂ÷) : 2018-08-26 0 912 2018-08-08
319 ¼­¿ï °í·Á´ëÇб³¾È»êº´¿ø Á¦14ȸ °í·ÁÀÇ´ë ÇǺΰúÇб³½Ç ½ÉÆ÷Áö¾ö ¹× ¿öÅ©¼ó : 2018-08-26 0 708 2018-08-08
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷